Lv2
200 积分 2022-07-16 加入
Primary and metastatic malignancies of the lung: Retrospective analysis of the CT-guided high-dose rate brachytherapy (CT-HDRBT) ablation in tumours <4 cm and ≥4 cm
2天前
已完结
Perkutane CT-gesteuerte Hochdosis-Brachytherapie (CT-HDRBT) von primären und metastatischen Lungentumoren in nicht chirurgischen Kandidaten
2天前
已关闭
Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
7天前
已完结
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer
1个月前
已关闭
Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial
1个月前
已完结
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?
1个月前
已完结
Fraction Dose Escalation of Hypofractionated Radiotherapy with Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non–Small Cell Lung Cancer: A Phase I Study
1个月前
已完结
Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
1个月前
已完结
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
1个月前
已完结
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial
2个月前
已完结
皖公网安备34019202002308
